Ascendis Pharma (ASND) - Company Revenue

The innovative TransCon system provides Ascendis Pharma A/S (ASND) with significant pricing power and stable demand. Corporate sales confirm this potential, while the 1.22 mark reflects the latest data. However, expensive climate-controlled transportation and the costs of implementing laboratory robotics create certain financial risks for the company's operations.

ASND Ascendis: Company Revenue in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Ascendis Pharma A/S

- price and consensus price forecast:

Stock Price Ascendis|ASND - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Ascendis Pharma A/S|ASND - Total Company Value

- book capitalization information:

Net Asset Value per Share Ascendis Pharma|ASND - Company Book Value|Market Value to Book Value Ratio ascendispharma.com|ASND - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

ASND - Net Profit|Future Profit Ascendis Pharma A/S|ASND - P/E Multiple|Projected Price to Earnings Ratio ascendispharma.com|ASND - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Ascendis Pharma A/S|ASND - Operating profit EBITDA|Earnings per share for the last 12 months Ascendis Pharma|ASND - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ascendispharma.com|ASND - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Ascendis Pharma A/S

- sales volume and revenue indicators:

ASND - Company Sales|Company Future Revenue Ascendis|ASND - Price-to-Revenue Ratio|Future Price to Revenue Ascendis Pharma A/S

Comprehensive company analysis:ASND Ascendis

Manufactured product of Ascendis Pharma Inc.

Sales reflect the total volume of products sold, serving as a primary indicator of market demand and financial stability. By analyzing the sales figures of Ascendis Pharma A/S (ASND), an investor can observe the actual dynamics of cash inflows from core operations. This metric is calculated as the sum of all transactions, reacting sensitively to changes in sales volumes. For Ascendis Pharma A/S (ASND), increasing values confirm the commercial success of prolonged-release drugs, which solidifies patient loyalty to unique endocrine therapies.

Key competitors